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Abstract
Lung cancer is one of the leading causes of cancer death among both men and 
women, making up almost 25% of all cancer deaths. Precision medicine shows 
promise for improving many aspects of health and healthcare, including tests, drugs, 
and other technologies that support innovation, with the possibility of new part-
nerships with scientists in a wide range of specialties. Non–small-cell lung cancer 
(NSCLC) has become a prominent example of the success of precision medicine in 
treating solid tumor malignancies. The first step in this process involves new blood-
based diagnostics, which can now noninvasively provide clinically useful informa-
tion. However, the identification of novel biomarkers that could be used in early 
diagnosis is urgently needed, especially for guiding initial therapy and predicting 
relapse or drug resistance following the administration of novel targeted therapies.
Keywords: precision medicine, target therapy, liquid biopsy, CTC, CSCs, miRNA, 
NGS, NSCLC
1. Introduction
1.1 Lung cancer and the meaning of “precision medicine”
The scientific community tends to conflate the meanings of “precision 
 medicine” and “personalized medicine” [1, 2]. In fact, the National Research 
Council defines “personalized medicine” with an old meaning quite similar to that 
of “precision medicine.” However, whereas personalized medicine mainly focuses 
on medical actions for a single person, precision medicine explores various factors 
affecting that person’s condition, such as diseases, the environment, etc. [3].
Precision medicine is able to provide specific genetic maps for patients with 
elevated cancer risks, potentially revealing gene mutations and thus calculating the 
likelihood of family members’ developing a certain type of cancer.
Recently, the use of precision medicine has been expanded to attempt treatment 
of several solid tumors, including those of breast, brain, and lung cancer [4, 5]. In 
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general, the aim of precision medicine is to find the right treatment for a specific 
patient at the right dose and time, which is particularly important in cancer therapy.
Finding a precise treatment for a patient could eradicate the potential problem 
of the variability of treatment response, including resistance. In fact, one of the 
main problems with cancer treatments is a nonresponse to drug therapy and the 
consequent metastatization of the disease.
Precision medicine is being used to treat certain cancers to help discover what 
tests and treatments are best. In addition, doctors could employ precision medicine 
to identify those at high risk for cancer, to prevent certain types of cancer, for early 
cancer detection, to make specific cancer diagnoses, to select the best treatment 
options, and to evaluate treatment efficacy [6].
The history of focused therapies to combat lung cancer began with the approval 
of the small molecule tyrosine kinase inhibitors (TKIs) of epidermal growth 
factor receptor (EGFR) [7]. This marked the beginning of the era of targeted 
therapies for lung cancer. On a related note, in 2004 and 2007, the first discoveries 
of adenocarcinoma of the lung were identified as EGFR mutations and ALK-
rearrangements. These new findings paved the way for new targeted therapies – 
namely, tyrosine kinase inhibitors (TKIs) [8]. The responses to these inhibitors 
and the subsequent discoveries from numerous clinical trials (NCT00322452, 
NCT00932893) [9, 10], led to incorporating them into daily clinical activities. This 
demonstrated that TKIs are more effective than traditional treatments, such as 
chemotherapy. In contrast, patients with non-EGFR mutant lung cancers do not 
respond to EGFR TKIs, and, for this reason, chemotherapy a more effective treat-
ment for them [9]. To complicate cancer’s frequent resistance to chemotherapy, 
consequent threat of recurrence, and the related costs of targeted therapies, no 
drugs have been very effective in its treatment. Thus, the latter must be considered 
when introducing targeted therapies into clinical practice [11]. However, scientists 
have proceeded to define and characterize other oncogenic driver mutations in 
lung adenocarcinoma, such as KRAS. This mutation was first described in 1980 
[12, 13], with a presence of 25–30% in lung adenocarcinoma and high aggression, 
which is even more dangerous without specific targeted therapies. Interestingly, 
the first recent study with promising clinical data came from a Phase I trial, in 
which the KRAS G12C inhibitor AMG 510 shrank lung cancer tumors harboring 
KRAS G12C mutations [14, 15]. This highlighted the importance of identifying 
new drivers’ mutations therapies in lung cancer for decreasing mortality and 
recurrence. Other mutations have been identified in lung cancer, including ERBB2 
(3%), BRAF (2%), PIK3CA (1%), MAP2K1 (1%), and NRAS (1%), [16], although 
these are defined as niche mutations. Beyond the fact that these niche mutations 
are infrequent, they are no less dangerous, with a high level of mortality. On this 
subject, a recent study by Aramini et al. examined three cohorts of mutations 
selected from patients with lung adenocarcinoma [17]. These mutations were 
1) BRAF, c-MET, DDR2, HER2, MAP2K1, NRAS, PIK3CA, and RET; 2) K-RAS; 
and 3) EGFR. In this pilot study, the researchers demonstrated that niche muta-
tions exhibited an increased risk of death when compared with EGFR mutations 
and a similar risk of death when compared with KRAS mutations. This aspect is 
key in highlighting the importance of focusing attention not only on general muta-
tions but also on niche mutations to develop more effective cures in larger popula-
tions. In fact, a clinical trial is currently being conducted to better define the less 
common oncogenic driver  mutations (e.g., NCT01336634).
In lung adenocarcinoma patients, the importance of testing eventual genetic 
mutations introduced new diagnostic perspectives. These have enhanced the treat-
ment recommendations of the International Association for the Study of Lung 
Cancer (IASLC) and National Comprehensive Cancer Network (NCCN) for patients 
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with EGFR mutation and ALK positivity. Moreover, new mutations have been studied 
for diagnostic purposes, including ROS, RET, MET, BRAF, and HER2, although these 
are infrequent mutations [18–20]. These studies have laid crucial groundwork for 
creating more focused treatments tailored to each patient [18–20].
Precise molecular tests led to the correlation of EGFR mutations and sensitiv-
ity to gefitinib and erlotinib in lung adenocarcinoma, especially in non-smokers 
or low-smokers. The EGFR tyrosine kinase inhibitors (TKIs) are considered the 
baseline treatment for this cancer, although a high percentage of patients develop 
resistance to therapy and experience a disease recurrence within nine months 
[18]. However, scientists discovered new mutations, developing a more focused 
panel of patients’ genetic characteristics. These researchers discovered that 50% 
of patients developing tumor dissemination showed a secondary EGFR mutation, 
such as T790M, which has been used for developing new target therapies, including 
AZD9291 and CO-1686 [21].
ALK, ROS, and RET, defined as receptor tyrosine kinase gene rearrangements, 
present at a frequency between 1 and 8% in lung adenocarcinoma, although patients 
harboring ALK fusion or ROS1 mutations have positively responded to crizotinib and 
to TKIs. However, these patients frequently develop recurrence, probably due to an 
acquired resistance and from mechanisms which must be further investigated [22, 23].
The target of mutations is particularly difficult, especially the study of the mito-
gen activation pathway (MAPK). This has been of recent interest for its implications 
regarding lung adenocarcinoma development and the subsequent results of thera-
peutics. Specifically, the MAPK activation mechanism has been found frequently 
along certain KRAS amino acids. Currently, KRAS is considered an aggressive 
mutation for its impact on overall survival (OS) in early-stage NSCLC. Finding 
specific RAS inhibitors may open the door to new target treatments that improve 
long-term survival and responses to therapies, even in patients with KRAS muta-
tions. New treatments have been set against the downstream effectors of activated 
KRAS, such as MEK1/MEK2, PI3K, and AKT [24]. In addition, recent phase II data 
analyzing the inhibition of MEK1/MEK2 by selumetinib and docetaxel showed 
promising results in KRAS-muted patients [25].
Additional work on downstream effectors in the KRAS mutant pathway is 
crucial. Currently, several clinical trials employing the inhibition of PI3KCA, MEK, 
and PTEN are in progress [26].
Recently precision medicine is used not only in clinical practice to drive onco-
logical decision but also in patients with rare tumors, likely due to their frequency 
in these patients’ family histories. This aspect is important for making medical 
decisions, as well as for screening.
The most frequent tests used at this time are biomarker tests, chromosome 
tests, gene tests, and biochemical tests, all of which are derived from blood, saliva, 
a tissue biopsy, or body fluids. These tests are named as follows: DNA mutational 
analysis, genomic testing, proteomics, biomarker testing, tumor profiling, 
cytogenetics, next generation sequencing, or molecular testing [27, 28].
1.2 NSCLC biomarkers
The use of drugs against NSCLC in locally advanced or advanced stages may 
help identify targeted drugs, which are more useful and better tolerated, as well as 
more responsive against lung cancer. The latter remains a serious problem in the 
world, accounting for over 1.7 million deaths in 2018 [29], showing that therapies 
are still largely ineffective. In particular, EGFR and ALK are considered biomarkers 
that predict positive responses to specific drugs. However, not all patients with lung 
cancer show these mutations, and this is why not all patients respond to gefitinib, 
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erlotinib, or afatinib, which are currently considered the most effective against 
EGFR mutations [30, 31].
In addition, the ALK-positive gene is rare, occurring in approximately 5% of 
patients with NSCLC and eliciting production of a growth-promoting enzyme [32]. 
Patients who are ALK-positive are usually treated with crizotinib, a tyrosine kinase 
inhibitor that blocks the input of the growth signals to the nucleus of the cancer 
cell. Immunotherapy is the last defense against cancer, and it has been developed 
in the last decades, including cancer vaccines, oncolytic viruses, and administra-
tion of antibodies or recombinant proteins that co-stimulate or block the immune 
checkpoint pathways [33]. However, there is a pressing need to identify new targets 
specific to a larger cohort of patients with better outcomes than those of current 
chemotherapeutic treatments. This need has induced the scientific community to 
deeply analyze other mechanisms or approaches.
Although targeted drugs and chemotherapeutic agents may be useful for weeks 
or months against tumors in terms of disease control, the majority of tumor relapses 
occur after several months of treatment.
1.3 A new kind of drug treatment: Immune checkpoint inhibitors
A new class of drugs was recently developed by Allison et al. and named 
 checkpoint inhibitors [34, 35]. This group has the specific role of enhancing patients’ 
immunity, thus increasing their chances of fighting cancer. The first one created 
was nivolumab, followed by pembrolizumab, which targets a receptor called 
programmed cell death-1 (PD-1).
However, not all patients have shown high levels of PD-1 expression in their 
cancer cells, revealing the major limitation of these therapies. In fact, the prognostic 
role of PD-L1 in solid tumors such as lung cancer, melanoma, etc. is still debated 
[36]. In patients with an overexpression of PD-L1, the use of antibodies able to 
target PD-1 and PD-L1 is one of the main points to consider for the setting of more 
effective therapies [37]. However, for the low immunohistochemistry accuracy 
based on PD-L1, the use of this biomarker as a possible predictor for satisfying 
immunotherapeutic results against cancer is under examination [38]. The main 
shortfalls of this marker are, first, the different cut-off values of positivity in 
different solid tumors; second, the sensitivity, which is very variable as demon-
strated in several studies; and third, the potential involvement and impact of the 
tumor microenvironment associated with the use of other genes markers which, 
combined together, may be more helpful for a better-focused PD-1/PD-L1 blocking 
 immunotherapy [39].
In particular, pembrolizumab—a humanized antibody used in cancer immuno-
therapy as a programmed cell death 1 (PD-1) inhibitor—seems to improve survival 
significantly more than standard chemotherapy in NSCLC patients with an expres-
sion of PD-1 ligand ≥50% in cancer cells [40, 41]. In addition, in nonsquamous 
NSCLC patients the PD-L1 positively expression of at least 1% represents a good 
responder against antitumor action. This aspect highlighted the importance of the 
presence of at least 1% PD-L1 expression for the treatment of NSCLC patients, which 
seem to represent two-thirds of all NSCLC population [42, 43]. In contrast, for small 
cell lung cancer (SCLC) which represents 15% of all types of lung cancers, there 
are actually few choices of cancer treatments and no molecularly targeted drug has 
been approved. In particular, the potential role of PD-1/PD-L1 inhibitors in SCLC 
has not been yet considered [44]. Recently, the first study analyzing the PD-L1 
expression in SCLC has been conducted at Kyoto University Hospital, where the 
researchers analyzed the immunohistochemical expression of this marker in paraffin 
blocks from 39 patients affected by SCLC [45]. Although previous studies have been 
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conducted—most likely for the use of different types of antibodies—the expression 
was arbitrary, and this represented an impediment in the elucidation of the possible 
expression and role of PD-L1 in SCLC [46]. For the first time, the team from Kyoto 
University thought to use the standard PD-L1 antibody already tested in NSCLC 
with the same cut-off level (1%) as in NSCLC [45]. This approach was important to 
elucidate the presence of this marker, even in SCLC, although the correlation with 
the clinical aspects has not been yet defined.
In summary, all the aspects described would suggest that the use of PD-L1 as an 
exclusive biomarker in cancer may not represent a completely satisfying choice in 
terms of accuracy and efficacy. On the other side, at the moment, scientists cannot 
ignore the good responses against cancer that patients with at least 1% of positivity 
for PD-L1 show through the most-used checkpoint inhibitors [47]. In summary, 
further studies set on the combination among PD-1/PD-L1 pathways, the tumor 
microenvironment and other genes markers may open the way for new discoveries 
that are tailored to the individual patient and more effective against cancer.
2. Precision medicine and solid tumors
The development of new techniques and approaches to discovering signaling 
pathways to better understand tumor growth has opened to precision medicine for 
solid tumors [48].
In particular, the major field is to create future treatments tailored to each 
patient to improve their results against cancer. However, this aspect has not yet 
been focalized for the numerous difficulties related to the new cancer cells targets. 
Through current clinical trials, pharmaceutical companies are developing studies 
based on specific markers to find multiple options for the best treatment [49].
Recent advances regarding the biology behind these tumors have shown 
promising results. In several centers, patients are analyzed by RNA expression test-
ing and protein analyses [50, 51]. These genetic analyses have already been taken 
into consideration, especially for hereditary tumors. Certain companies, such as 
Myriad Genetics Inc., have developed in the last decades several molecular diag-
nostic kits to test patients at risk of developing hereditary tumors [52–54]. Thus 
far, this aspect has been extensively analyzed for prostate cancer and breast cancer 
[55, 56]. It has been examined for the genes mutations that are more frequent in 
these diseases, as well as the development of prognostic scores related to cancer 
 recurrence [57].
At the moment, the possibility of developing a molecular profile is limited for 
the presence of mutations and other genetic variations. However, scientists are 
planning to develop a molecular profile based on RNA expression, as described 
for familiar genetic diseases or by immunity profiles. There is an urgent need to 
develop new approaches and targeted treatments to better stratify cancer patients, 
to prevent recurrence, and to more effectively treat these patients.
Several clinical trials are running regarding the possibility of targeting oncologic 
patients. Some of these trials involve specific tumors, such as BATTLE I and II [58], 
and some are non-tumor specific. These studies have been designed as observa-
tional, randomized, and non-randomized [59–62].
Non-randomized trials are studying molecular profiles in the Clinical 
Laboratory Improvement Amendments (CLIA) certified laboratories, which 
were founded in 2013 in collaboration with pharmaceutical societies to identify 
a specific genes patent for each patient. In particular, pharmaceutical companies 
have been conducting independent trials of drugs in patients with specific genetic 
profiles [63].
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However, these profiles may not be the same for patients with several solid 
tumors, but at this time, this aspect is not well known. The National Cancer 
Institute (NCI) is preparing a study with the involvement of agents from different 
companies [64]. The baseline for these studies, called NCI-MATCH studies, will 
be the analysis by a consortium of NCI-selected CLIA-certified laboratories of the 
genomic profiles of several cancer patients. This process will use a new approach 
called next generation sequencing (NGS) for a number of selected genes.
Another interesting study, the SHIVA study, randomizes patients with specific 
genetic abnormalities matching generic types of cancer and patients’ specific genes. 
It examines the possible results from standard treatments in terms of cytotoxicity 
and disease progression [65].
These types of combined studies involving several companies and certified 
laboratories may be very important to further discoveries, but the difficulty of coor-
dinating multiple companies constitutes an effective impediment. Basic research 
is suggested to more deeply analyze the mechanisms and mutations involved in 
development and tumor progression [66, 67]. A representative panel during time of 
the major achievements for lung cancer therapy (Figure 1).
Regarding the mutations, those in the scientific community do not believe that 
studying a single mutation or a small panel of genes would be enough to influence 
future decisions or treatments for oncological patients. For this reason, the new 
advanced technologies require a larger panel of genes or intra- and inter-tumor 
heterogeneity at the protein, genetic, and epigenetic levels [68, 69]. Specifically, the 
genetic analysis of RNA and proteins in primary or metastatic diseases in patients 
with renal carcinomas have shown a large heterogeneity of cells and genes inside 
the tumors. This is one of the main obstacles in the battle against cancer [68, 69]. 
On the other hand, in colorectal and lung cancer, the panel of genes that seem to be 
involved is limited [70, 71]. One must be considered, such as in the case of lung can-
cer. Such a tumor could develop several mutations during its progression, and these 
would be persistent in evolving. For this reason, future patients’ tumor profiles 
Figure 1. 
Timeline of major discoveries and related therapeutic approaches in non-small cells lung cancer.
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would need to be frequently updated to guarantee the best treatment options. One 
problem would be the impossibility of obtaining sufficient material from biopsies. 
In addition, it would be difficult to ask to these patients to perform several biopsies 
in order to have a more focused treatment. Thus, in order to minimize invasive 
procedures, scientists have attempted to develop the best approach with the least 
aggressiveness toward the patient. For example, the analysis of circulating free 
DNA (cfDNA)by liquid biopsy, widely discussed at this time, and CTCs may be 
considered of great value if these approaches are able to replace multiple biopsies. 
For the moment, the results of these techniques seem to be promising, but further 
investigation is needed regarding each type of solid tumor, as well as each patient 
[72–74].
Even the serum proteins are of interest; however, the difficulty in identifying a 
specific protein has made this approach very difficult to use for tumor patients. For 
example, PSA levels for prostate cancer patients, as well as CEA measurements, are 
commonly used markers, but several clinical trials and basic research are necessary 
to identify more markers for future cancer diagnoses [75–77].
In summary, important progress has been made in terms of molecular profiles 
and developing advanced genetic technologies. However, the coming years will be 
crucial in determining whether these new aspects will revolutionize treatments and 
improve prognoses in cancer patients.
3.  Recent discoveries in precision-diagnostic and precision-therapeutic 
approaches to lung cancer
New genetic discoveries through high-throughput techniques could allow the 
establishment of a new era in which precision medicine could be routinely used 
for cancer treatment, as well as in its diagnosis and therapy [78]. Since the earlies 
2000s, innovative sequencing systems called next-generation sequencing methods 
(NGS, Next Generation Sequencing), or massive parallel sequencing (MPS, Massive 
Parallel Sequencing), have been used to define high-efficiency nucleotide sequences 
in the simultaneous, independent analysis of millions of bp of DNA. In particular, 
the association of genomic data and the identification of new biomarkers may 
modify cancer treatments in the near future. This would require extensive knowl-
edge of the mutational analysis of a panel of cancer genes, along with determination 
of copy-number variations and any other structural rearrangements. As with lung 
cancer, which has a high rate of recurrence after surgery independent from stages, 
it would be useful in treating other solid tumors to have some predictor of relapse 
based on genetic tests identifying the individual risks of various cancers and their 
consequent relapses. This chapter will discuss technical considerations for develop-
ing genomic precision diagnostic tools for clinicians to support their further use in 
oncological care and research trials, as represented schematically in Figure 2.
3.1 Single-gene assays versus next-generation sequencing
Until now, the most commonly used methods have included DNA or RNA 
amplification using polymerase chain reaction (PCR), followed by classical Sanger 
sequencing or pyrosequencing, analysis of fragments by electrophoresis after 
digestion with restriction enzymes, or fluorescent in situ hybridization with specific 
probes (FISH) [79]. Single gene analysis often has significant advantages over 
large-scale genomic sequencing due to the lower cost and reduced complexity in test 
development, execution, and interpretation. In molecular oncology, for example, 
there is frequent identification of BCR-ABL1 translocation by FISH in patients 
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with chronic myeloid leukemia. Single gene analysis is a useful approach when the 
genetic alterations are well known. On the other hand, high-throughput screening, 
such as NGS, is more sensitive than many monogenic methodologies, such as Sanger 
sequencing. As a consequence of the discovery of more relevant genes in a clinical 
context, NGS has become an increasingly attractive approach. Molecular testing 
of advanced non-small cell lung cancer (NSCLC) provides a good example of the 
rapidly growing need for the molecular profile of several genes, especially cancer. 
Initially, the only knowledge about the genetics of lung cancer was the deletion of 
exon19 in the EGFR gene and the mutation of the L858R gene, which could lead to 
the first targeted therapy with tyrosine kinase inhibitor (TKI) [80–88]. However, 
within a few years, effective targeted therapies approved by the U.S. Food and Drug 
Administration (FDA) have been developed and are now effective in treating lung 
cancer with other EGFR and BRAF mutations [83, 84], as well as ALK and ROS1 
rearrangements [84–88]. Other solid tumors have been associated with target 
therapies involving other molecular alterations, such as exon 14 MET skip muta-
tions [89–91], RET rearrangements [92–94], and ERBB2 (HER2) mutations [95], 
which have led to a new setting for therapeutic recommendations from the National 
Comprehensive Cancer Network (NCCN) [96].
3.2 Gene panels versus unbiased genomic and transcriptomic analyses
Given their high speed of execution, NGS techniques have been used for the 
identification of disease genes by whole genome sequencing (WGS) or whole exome 
sequencing (WES), as well as target gene panels [97]. The potential advantage 
of these techniques is the possibility of detecting essentially any genomic altera-
tion, including novel or rare alterations. However, certain critical points must be 
considered. To begin, WGS is far too expensive and generates a huge amount of 
raw data requiring complex bioinformatics analyses to extract useful information. 
Figure 2. 
Future perspectives in molecular profiling and diagnostic approaches in lung cancer.
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As a consequence, analysis may be performed only on selected cases. In NSCLC, 
for instance, whole-genome studies have demonstrated a median of 888 and 
15,659 mutations in NSCLC samples from, respectively, nonsmokers and smokers 
[98]. The major part of these variants lacks any relevant pathogenic significance. 
Nevertheless, the comparison between tumor and normal DNA is mandatory, dis-
tinguishing somatic mutations, due to cancer, from germline polymorphisms, which 
will be inherited by patients’ offspring. However, WES is an unbiased approach 
that has also found utility in certain laboratories as a tool for unraveling cancers. 
WES limits sequencing to the ∼1.5% of the genome that lies in the exons of genes. 
Nevertheless, this approach also generates a large number of potential variants, the 
vast majority of which even in this case currently do not have annotated clinical 
implications. Exome sequencing would also fail to detect pathogenic variants, such 
as structural rearrangements with intronic breakpoints. DNA quality requirements 
are lower than those of WGS, so the drawbacks of this approach include the fact that 
the depth of sequencing obtained through WES is much lower than that obtained 
from targeted panels. For diagnostic purposes, it has been argued that a high 
sensitivity is needed to reduce the number of false negatives. Although a genetic 
variant of uncertain significance can be detected, it would be better to be cautious 
even if there were no clinical treatment for the alteration. Another crucial element 
that may be investigated with WGS is the copy number alteration (CNA), which is 
a parameter that takes into account the number of repeated alterations in the DNA. 
These hallmarks in cancer often lead to the activation of oncogenes and inactivation 
of tumor suppressor [99]. The WES is primarily used to discover all of the variations 
in the DNA sequence, but the RNA-Seq is specifically used for the measurement of 
gene expression, gene fusion detection, and identification of splicing events, since 
it is based on direct sequencing of cDNA. One of the most important applications of 
the RNA-Seq is for cancer. For example, a large-scale RNA-Seq has been useful for 
the detection of several cancer driver genes in adenocarcinoma of the lungs [100, 
101]. That study compared the transcriptome of lung cancers between smokers and 
nonsmokers and found a significant difference in the number of point mutations 
between the two groups. In summary, the amount of smoking (packs/year) was 
positively correlated with the number of somatic point mutations in the cancer 
genome. As for the study described, a complete molecular analysis conducted on 
the transcriptome or the entire genome or exosome through higher coverage of 
the genomic regions allowed the detection of lower-level molecular alterations. 
Moreover, the principle difference between targeted genetic panels and unbiased, 
extensive genomic and transcriptomic analysis is not necessary in the last case to 
know a priori the molecular alterations to be detected.
3.3 Applications of molecular oncology
3.3.1 Diagnosis
For different tumors, molecular diagnostic tests, as for example, BCR-ABL1 
in chronic myeloid leukemia or other data, may be very helpful in influencing 
the decisions of oncologists or pathologists. That is, they could develop more 
detailed diagnoses, as well as more appropriate approaches, although molecu-
lar analyses would need to be correlated with clinicopathological patients’ 
characteristics.
In particular, certain mutations detected in malignant tumors have also been 
found in healthy individuals [102–104]. However, the new technologies related to 
advanced molecular analysis are now able to distinguish between cancer mutations 
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and normal tissue mutations. One of the most important aspects of this preci-
sion medicine tailored to the patient is the possibility of stratifying the prognosis. 
Several studies are examining this aspect in several solid tumors [105–108].
3.3.2 Therapy
Several clinical trials are currently being conducted regarding specific 
 target alterations in different cancer types. The Molecular Analysis for Therapy 
Choice (MATCH; http://www.cancer.gov/aboutcancer/treatment/clinical-trials/
nci-supported/nci-match) trial and the Targeted Agent and Profiling Utilization 
Registry (TAPUR) trial were designed to identify particular molecular targets able 
to determine a specific therapy against cancer. The main difficulty arises from 
the fact that each tumor shows a specific mutation that may be different in each 
patient. This genetic heterogeneity has led to targeting specific drivers in each 
tumor. Furthermore, the identification through the NGS technique introduced 
new possibilities for finding specific oncogenic drivers that could maximize the 
possibility of receiving the benefit of a very focused, tailored therapy. The use of 
NGS is intended to guide treatment decisions. In fact, this technique can identify 
oncogenic alterations, which may be target inhibitors or monoclonal antibodies. 
For example, the BRAF V600E mutation can be cured by BRAF inhibitors and MEK 
inhibitors approved by the FDA. For instance, patients with colorectal cancer and 
KRAS and NRAS mutations showed a therapeutic resistance to EGFR antibody 
therapy [109, 110].
The integration of genomic results into reports and the clinical decision sup-
ported by NGS are a powerful tool that enables the simultaneous interrogation of 
many regions of the human genome [111]. However, as the volume of data from 
NGS testing grows, so does the challenge of distinguishing the findings that are 
clinically meaningful and prioritizing their clinical utility. Given the large number 
of genetic variants that occur in cancer genomes and the many low-frequency or 
nonrecurring mutations detected using NGS, a systematic approach to prioritizing 
variants is necessary to effectively implement NGS-based precision diagnostics in 
routine clinical contexts [112]. Molecular pathologists, in collaboration with their 
oncology colleagues, have been tasked with evaluating this abundance of data, 
distilling it to what is clinically relevant, and communicating this information in 
the most cogent, manageable manner possible. Several components are required 
to properly integrate genomic results into clinical reports, among which is the 
 understanding of the clinical evolution of the genomic variant in patients.
4. Future perspectives on lung cancer treatments
The role of cfDNA has been extensively analyzed in terms of the definition of 
new-targeted therapies, and the interpretation of this role in driving immuno-
therapy has just begun [113]. The mutation in a cancer patient can be studied from 
cfDNA by NGS [114]. Only one study has found conflicting results from the blood 
tumor mutation burden (TMB) [115]. It has been found that a high blood sample, 
TMB, is correlated with the reaction to inhibitors of programmed cell death (PD)1 
and its ligand (PD-L1) [115, 116], as in NSCLC with atezolizumab in POPLAR 
and OAK trials [117]. The TMB is more correlated with advanced disease, and it 
expresses a high value of circulating tumor DNA (ctDNA) concentrations [118]. 
Different studies have shown that there is a correlation between ctDNA kinetics 
and clinical course in terms of possibility of predicting the prognosis [119]. In 
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particular, it has been demonstrated that the variation of circulating the tumor 
DNA burden is able to distinguish a real and unreal tumor progression. Another 
interesting application of cfDNA, which scientists are studying, is the possibility of 
detecting the minimal residual disease (MRD) for the setting of immunotherapy 
or the possibility of finding the drug resistance as JAK1/2 or B2M mutations [120]. 
With regard to the early stages’ NSCLC, the prospect of setting screening tests 
is very challenging. The National Lung Screening Trial [121] and the NELSON 
trial have shown that to test asymptomatic men with high risks factors by chest 
CT reduced the deaths in men to 26% and in women to 41% [122]. However, the 
problem of false positives is still one of the most difficult factors to eliminate [123]. 
These trials showed that the combination of the high sensitivity of CT scans and 
liquid biopsy may have an important effect in driving clinical decisions, as well 
as therapeutic approaches. One limitation is the fact that ctDNA quantities may 
be low or absent in the early stages of disease [124]. Another important value of 
cfDNA assay may be the opportunity to identify recurrent mutations. This aspect 
is important in terms of prognosis and developing new targeted treatments. For 
example, the Cancer SEEK assay can combine the genomic analysis of 16 genes in 
ctDNA and eight biomarkers detectable for eight non metastatic diseases [125–127]. 
Nevertheless, certain limitations remain regarding sensitivity to early-stage detec-
tion. For instance, lung cancer does not currently have a specific circulating protein 
marker. The most promising test at the moment is the multi-region exome sequenc-
ing of a tumor, but this technique is limited by the costs and the excessive time 
required, which make this approach currently unavailable to the patients. However, 
the most discussed approaches developed for circulating tumor cells (CTC) isola-
tion are based on the following: 1) antigen expression and 2) biophysical character-
istics [128–130].
In summary, the microfluidic technologies have probably been the most com-
mon approach to CTC isolation since 2007, with the “CTC-ship” [131]. However, 
several limitations are ongoing, and further studies must better stratify this 
approach not only in the early stages of NSCLC but also for other solid tumors. 
The world of exosomes is complex because of their vast numbers and various 
roles. In particular, they were found to contain microRNA (miRNA) that could be 
exchanged via horizontal intercellular transfer with the possibility of activating 
an oncogene or a tumor suppressor gene. In 60–75% NSCLC, miRNAs play crucial 
roles. Moreover, recent studies have provided evidence that exosomes may mediate 
interactions among different types of cells to enhance cell–cell communication 
within the tumor microenvironment. In particular, exosome signaling may provide 
new insights into how cancer stem cells (CSCs) confer drug resistance between 
drug-resistant and drug-sensitive cells [132]. In fact, CSCs exhibit self-renewal, 
proliferation, tumor initiation, and propagation, and the “stemness” of cancer 
cells seems to be supported by the release of exosomes [133–135]. Cancer stem cells 
are thought to secrete microvesicles and exosomes that interact with neighboring 
stromal cells. For instance, experimental evidence has shown that breast cancer 
stem cells secrete exosomes with characteristics of cancer cell-derived exosomes 
[135, 136]. Exosomes released by cancer stem cells mediate tumor growth in dif-
ferent cancer types. For example, in a renal cancer model, microvesicles released 
from human renal cancer stem cells were described to stimulate angiogenesis and 
the formation of a pre-metastatic niche in the lungs [137]. Elsewhere, a study on 
glioma stem cells reported that glioma-associated stem cells increased the bio-
logical aggressiveness of glioma-initiating cells through the release of exosomes. 
However, both exosomes and cancer stem cells targeted against tumors must be 
thoroughly analyzed in the future. This is important because there is no clear 
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identification of a specific target against NSCLC [138, 139] or tumors in general, 
and it is difficult to characterize cancer stem cells and necessary to optimize the 
roles and definitions of specific exosomes for each type of cancer. Such research 
would be a milestone in developing new therapies and new approaches to screen-
ing oncologic patients.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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